What do FGFR Genetic Mutations Mean for You and Your MBC? - Metastatic Breast Cancer Trial Talk

Research News

As tumors grow, they often develop various types of mutations (changes in the DNA code) and other genetic abnormalities that help them survive and grow. Researchers are developing new medications that target tumors with particular genetic abnormalities.

FGFR (fibroblast growth factor receptor) is a family of proteins that helps cells grow. When the FGFR gene, which provides instructions to make the FGFR protein, is abnormal, the FGFR protein may become overactive and stimulate tumor cells to grow faster. Around 7% of breast cancers have abnormalities in the FGFR gene. Research also suggests that abnormalities in the FGFR gene play a role in resistance to endocrine treatment and CDK4/6 inhibitors. As a result, trials to test drugs called FGFR inhibitors that target the FGFR protein are underway.

Read below to learn more about how FGFR works, recent research into how abnormalities in the FGFR gene may affect treatment resistance and response to FGFR inhibitors, and two journal articles that show a list of FGFR inhibitors that are being tested in breast cancer clinical trials.

General Information About FGFR Abnormalities In Cancer
FGFR Abnormalities and Treatment Resistance
List of FGFR Inhibitors Being Tested In Clinical Trials



for past articles or specific information.